Neurolupus and Updated Therapeutic Drug
Author(s): Lourdes de Fatima Ibanez Valdes, Humberto Foyaca Sibat*
Abstract
Introduction: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that affects many organs and systems, including the kidneys, neurological system, blood cells, skin, joints, and serous membranes. It is characterized by a broad, varied clinical phenotype and course. Goals: To look for new knowledge.
Methods: To discover articles pertaining to new information on GA and diagnostic techniques, a thorough search of the medical literature was conducted using the databases PubMed/MEDLINE, Scopus, and Embase. We used the PRISMA standards to search the medical literature from January 1, 1990, to January 30, 2026. The following terms were used by the authors to search the scientific databases Scopus, Embassy, Medline, and PubMed Central: “systemic lupus erythematosus” OR “neurorolupus” OR “neuropsychiatric systemic lupus erythematosus” OR “lupus cerebritis” OR “autoantibody” OR “ “neurological symptoms of SLE” or “CNS lupus.”
Results: 297 articles were found through a literature search. 108 publications were chosen after 189 duplicate titles and abstracts were eliminated. 35 research examined the impact of autoantibodies on the pathophysiology of NPSLE after 53 papers were eliminated based on the inclusion/exclusion criteria.
Conclusions: Apoptotic debris, INF-alpha production, B cell expression, CD40L, interleukin 21, and helper T cells are the key components in the pathophysiology of NPSLE.